Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11779612 | PMC |
| http://dx.doi.org/10.3389/fimmu.2024.1548624 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition.
Front Oncol
January 2025
Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Background: Dedifferentiated liposarcoma (DDLPS) is a rare mesenchymal cancer originating from the adipose tissue, with poor survival rates for most patients, highlighting the critical need for novel treatment options.
Case Description: This report examines the efficacy and safety of sequential pre-treatment with the marine-derived alkaloid trabectedin followed by checkpoint inhibition using the anti-PD-1 antibody nivolumab in a 63-year-old male patient with unresectable retroperitoneal DDLPS. Treatment was initiated at the time of the seventh relapse as part of the NitraSarc phase 2 multicenter trial for inoperable soft tissue sarcoma conducted by the German Interdisciplinary Sarcoma Group (GISG-15, ).
Serum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting.
Alzheimers Dement (Amst)
January 2025
Neurochemistry Laboratory Department of Laboratory Medicine Amsterdam UMC Amsterdam The Netherlands.
Introduction: Blood-based glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau (pTau) have shown promising prognostic potential in Alzheimer's disease (AD), but their applicability in clinical settings where comorbidities are prevalent remains uncertain.
Methods: Simoa assays quantified GFAP, NfL, and pTau181 in retrospectively retrieved prediagnostic serum samples from 102 AD patients and 21 non-AD controls.
Results: Higher serum GFAP levels predicted earlier clinical presentation and faster subsequent Mini-Mental State Examination decline in AD patients.
Machine learning predicted fast progression after initiation of immune checkpoint inhibitors in advanced non-small cell lung cancer.
BMJ Oncol
February 2024
NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia.
Unlocking the predictive power of imaging biomarkers: predicting immune checkpoint therapy response in non-small cell lung cancer through baseline tumour vessel perfusions.
BMJ Oncol
August 2024
Radiation Medicine Program, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
Determining fracture risk in patients exposed to immune checkpoint inhibitors: the time is now.
BMJ Oncol
August 2024
Medicine, Dalhousie University, Halifax, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!